Ace the Case: A 62-Year-Old Man With Monoclonal Protein Detected on Routine Blood Work

This educational activity will utilize a case study to discuss the diagnostic and management options for a patient with smoldering multiple myeloma. 

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, medical oncologists, and other health care providers involved in the care of patients with multiple myeloma.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to describe the benefits and limitations of treatments for patients with smoldering multiple myeloma. 

Additional Information

Partner: 
The Penn State College of Medicine
Course summary
Available credit: 
  • 25.00 MOC
  • 0.25 AMA PRA Category 1 Credit™
Course opens: 
08/20/2020
Course expires: 
08/20/2021
Rating: 
0

Nina Shah, MD
Associate Professor of Medicine
University of California San Francisco
San Francisco, California

Disclosures

In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.

Nina Shah, MD, has disclosed the following relevant financial relationships:
Consultant/Advisor: Amgen, Bristol Myers Squibb, CareDx, Genentech, GlaxoSmithKline, Indapta Therapeutics, Karyopharm Therapeutics, Nektar Therapeutics, Oncopeptides, Precision BioSciences, Sanofi, Seattle Genomics, Surface Oncology
Research Grant: Bluebird Bio, Celgene/Bristol Myers Squibb, Janssen, Sutro Biopharma, TeneoBio  

Penn State College of Medicine
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Multiple Myeloma Research Foundation 
Mary DeRome, Director of Medical Communications and Education, has disclosed no relevant financial relationships.

RedMedEd
Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships.
Kristen Petro Slade, Director of Operations, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Karen Smith, Creative Director, has disclosed no relevant financial relationships. 
Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Penn State College of Medicine; RedMedEd; the Multiple Myeloma Research Foundation; Adaptive Biotechnologies; Amgen; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Karyopharm Therapeutics; Oncopeptides; and Sanofi Genzyme do not recommend the use of any agent outside the labeled indications.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Penn State College of Medicine designates this enduring material for 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to the ACCME for the purpose of granting ABIM MOC points.

This enduring material is approved for 1 year from the date of original release, August 20, 2020 to August 20, 2021. 

Available Credit

  • 25.00 MOC
  • 0.25 AMA PRA Category 1 Credit™
Please login or register to take this course.

This course is offered through Penn State College of Medicine. To take this course you will be redirected to Penn State College of Medicine's website. You must have an account with Penn State College of Medicine in order to complete this activity.  

Mocingbird continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!